Friday, 20 Apr 2018

You are here

RheumNow Week in Review – 22 July 2016

Highlights from this week on RheumNow.com include:

  1. In Tofacitinib developmental trials in RA and Psoriasis, there were 1821 women of child-bearing age who were exposed; 47 became pregnant (33 monoRx). There were no deaths and one congenital malformation (1 Pulmonic valve stenosis), 7 Spontaneous Abortions. http://buff.ly/2azDHwd
  2. BMS has a new autoinjector for abatacept (ORENCIA) called "ClickJect" with a 15 sec delivery duration https://t.co/6QHIqK51Pj
  3. Between 10-50% of colorectal cancer patients have a positive ANA by either EIA or IIF. Small study but instructive. https://t.co/WWMbH3J4Vw
  4. Pirfenidone is FDA approved for IPF. Open label study 63 PSS patients with IPF show it tolerable and safe but no effect on outcomes https://t.co/j2ujvmfMnF
  5. NEJM article by Drs. Taurog & Colbert review ankylosing spondylitis & Spondyloarthritis. https://t.co/L6lQSi9Gyn
  6. RWCS Pearl: Dapsone can be of benefit in SCLE patients who do not respond to antimalarials. https://t.co/5cOXVH42Xi
  7. WEGENT compared outcomes in 112 GPA & MPA patients; Imuran & MTX had similar 10 yr survival, relapse rates, & toxicities https://t.co/dIl4wnsRzY
  8. Adherence to T2T in 198 early RA pts had no effect on Xrays or 12 mos DAS, but significantly improved DAS & functional outcomes at 3 yrs. https://t.co/XrXhnEkkUl
  9. MTX in Psoriatic arthritis achieves MDA – minimal disease activity criteria in <20%. MDA defined as 5 or more of the following 7 criteria: SJC, PASI, entheses≤1, BSA≤3%, HAQ≤0.5, pt global≤20, Pt pain≤15. https://t.co/dO6qyys8yy
  10. Epigenetic Changes to Inflammasome Found in Autoinflammatory Syndromes. 
  11. DEXA Still Needed While on Bisphosphonates: a study of 6629 Canadian women with osteoporosis taking bisphosphonates finds ~20% have decrease in bone density on medication
  12. Prevalence of Spondyloarthropathy in Fibromyalgia. Sacroiliitis found in 8% of 99 FM patients. Axial SpA found in 10%. Inflammatory MRI imaging changes found in 17% to 25% of patients. 
  13. Will Patent Extensions Delay Biosimilar Arrivals
Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.